Status:
RECRUITING
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Artidis
Conditions:
Breast Carcinoma
Invasive Breast Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target c...
Detailed Description
PRIMARY OBJECTIVE: I. To estimate the percent change in immune infiltration at day 3 and day 7 of radiotherapy (RT) relative to baseline (before radiotherapy). SECONDARY OBJECTIVE: I. To estimate t...
Eligibility Criteria
Inclusion
- Patients \>= 18 years of age with biopsy proven invasive breast cancer
- Breast cancer that appears to be superficially accessible to a tumor punch biopsy
- Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
- In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
Exclusion
- A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
- Pregnancy
- Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
- Receipt of immunotherapy or chemotherapy 7 days prior to start of RT
Key Trial Info
Start Date :
September 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05406232
Start Date
September 15 2023
End Date
December 31 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030